Peps
What is Pemvidutide?
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis (MASH). Its liver-biopsy outcomes should be separated from weight-loss claims.
Biological role or research focus
Metabolic liver-disease research.
Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
Names you may encounter
ALT-801
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Dual GLP-1 / glucagon receptor agonist
- Research focus
- Metabolic liver-disease research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
How Pemvidutide works
The investigational approach combines incretin and glucagon pathways. The IMPACT study examined liver histology, testing both resolution of steatohepatitis and improvement in fibrosis.
Clinical context & research status
The selected phase 2b report concerns biopsy-confirmed MASH with stage F2 or F3 fibrosis. It is not evidence of treatment for every fatty-liver diagnosis or of reduced liver-related mortality.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2025
IMPACT
Did MASH resolve and did fibrosis improve?
- Population / model
- 212 adults with biopsy-confirmed MASH and F2 or F3 fibrosis.
- Study design
- Randomized placebo-controlled phase 2b study; this publication reports the 24-week analysis of a planned 48-week trial.
- Main finding
- MASH resolution without worsening fibrosis occurred in 58% and 52% of the pemvidutide groups versus 20% with placebo. Fibrosis improvement without worsening MASH was 33% and 36% versus 28%; these fibrosis comparisons were not statistically significant.
- Limits & context
- Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. ↗
Journal of hepatology · 2025 Jan · Journal Article, Randomized Controlled Trial, Multicenter Study
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. ↗
Peptides · 2025 May · Journal Article, Review
Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. ↗
Journal of cachexia, sarcopenia and muscle · 2025 Dec · Journal Article
Read available full text ↗
Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial. ↗
JHEP reports : innovation in hepatology · 2025 Nov · Journal Article
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Most adverse events were mild or moderate in the reported study. A phase 2b trial of this size and duration cannot establish long-term safety or uncommon harms.
Identity, route, and evidence limits
Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Did this study prove fibrosis reversal?
- What population, comparator, and route were actually studied?
- Short-term biopsy outcomes are different from cirrhosis prevention, transplantation, or survival. A positive MASH-resolution result does not turn the nonsignificant fibrosis outcome into a proven benefit. Altimmune funded the trial.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did this study prove fibrosis reversal?
No. The reported fibrosis-improvement comparisons did not reach statistical significance, even though MASH resolution was more frequent.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.